FDA inspection
Acino Products, LLC: FDA inspection ending Jul 1, 2021
FDA inspection 1145772 · Official Action Indicated (OAI) · Hamilton, NJ
Key facts
| Inspection ID | 1145772 |
|---|---|
| Firm | Acino Products, LLC |
| FEI number | 3004723334 |
| Address | 9b S Gold Dr |
| City | Hamilton |
| State | NJ |
| ZIP | 08691-1642 |
| Fiscal year | 2021 |
| Inspection end date | Jul 1, 2021 |
| Classification | Official Action Indicated (OAI) |
| Project area | Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs|Unapproved and Misbranded Drugs |
| Product type | Drugs |
At a glance
- 10–99 Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 10–99 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data